Novo Nordisk shares pop after Wegovy receives U.S. approval for liver disease

cnbc.com/2025/08/18/novo-nordisk-shares-pop-5percent-after-wegovy-receives-us-approval-for-liver-disease.html

Shares of Novo Nordisk climbed Monday after the company's blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease.
The company on Friday said that it was granted approval for the treatment of metabolic…

This story appeared on cnbc.com, 2025-08-19 12:59:31.464000.
The Entire Business World on a Single Page. Free to Use →